Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Ole B. Suhr, Sunita Goyal et al.|New England Journal of Medicine|2018Cited by 2.9k
Utility of the Rio Score and Modified Rio Score in Korean Patients with Multiple SclerosisJae‐Won Hyun, Ho Jin Kim, Su‐Hyun Kim et al.|PLoS ONE|2015Cited by 19
Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrumSu Yeon Park, Young Nam Kwon, Sun‐Young Kim et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 18
Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseasesJae‐Won Hyun, Ho Jin Kim, Hye Lim Lee et al.|Multiple Sclerosis Journal|2020Cited by 14
Characteristics of South Korean Patients with Hereditary Transthyretin AmyloidosisKyomin Choi, Jeeyoung Oh, Jin-Myoung Seok et al.|Journal of Clinical Neurology|2018Cited by 14